HomeTrialNCT06809400
🔬NCT06809400Phase 1RECRUITING

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Study Summary

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment127 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866296+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.